Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

18.58
+1.589.26%
Post-market: 18.940.3673+1.98%19:59 EDT
Volume:3.90M
Turnover:71.94M
Market Cap:1.87B
PE:-4.06
High:18.97
Open:17.63
Low:17.33
Close:17.00
Loading ...

Beam Therapeutics Confirms Key Decisions at Annual Meeting

TIPRANKS
·
Yesterday

Bernstein Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
06 Jun

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks
·
04 Jun

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks
·
04 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global

Reuters
·
04 Jun

Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data

GlobeNewswire
·
03 Jun

Beam Therapeutics Inc. Receives FDA Orphan Drug Designation for BEAM-101 in Sickle Cell Disease Treatment

Reuters
·
03 Jun

Beam Therapeutics Inc - Beam-101 Safety Profile Consistent With Busulfan Conditioning

THOMSON REUTERS
·
03 Jun

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease

THOMSON REUTERS
·
03 Jun

Beam Therapeutics treatment of sickle cell disease granted orphan designation

TIPRANKS
·
31 May

Sector Update: Health Care Stocks Fall Pre-Bell Friday

MT Newswires Live
·
30 May

Beam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver Treatment

Dow Jones
·
30 May

Beam Therapeutics receives orphan drug designation for BEAM-302

TIPRANKS
·
30 May

Beam Therapeutics Inc - Initiates Dosing in Fourth Cohort, Data Expected in H2 2025

THOMSON REUTERS
·
30 May

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS
·
30 May

Beam Therapeutics Inc - to Dose First Patient in Part B of Trial in H2 2025

THOMSON REUTERS
·
30 May

Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status

TIPRANKS
·
29 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)

TIPRANKS
·
25 May

Beam Therapeutics Inc. to Participate in RBC Capital Markets Global Healthcare Conference

Reuters
·
13 May

Beam Therapeutics announces FDA grants RMAT designation to BEAM-302

TIPRANKS
·
13 May